Lara Meisner - 02 Jun 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Legal Officer
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Issuer symbol
VRDN
Transactions as of
02 Jun 2023
Transactions value $
-$55,767
Form type
4
Date filed
06 Jun 2023, 19:41
Previous filing
10 Mar 2023
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $26.3K +1.88K +6.26% $14.00 31.8K 02 Jun 2023 Direct
transaction VRDN Common Stock Sale -$45.4K -1.88K -5.89% $24.21 30K 02 Jun 2023 Direct F1
transaction VRDN Common Stock Options Exercise $9.24K +499 +1.66% $18.51 30.5K 05 Jun 2023 Direct
transaction VRDN Common Stock Sale -$12.5K -499 -1.64% $25.03 30K 05 Jun 2023 Direct F2
transaction VRDN Common Stock Options Exercise $94.9K +5.13K +17.1% $18.51 35.1K 06 Jun 2023 Direct
transaction VRDN Common Stock Sale -$128K -5.13K -14.61% $25.02 30K 06 Jun 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -1.88K -9.37% $0.00 18.1K 02 Jun 2023 Common Stock 1.88K $14.00 Direct F4
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -499 -0.55% $0.00 89.5K 05 Jun 2023 Common Stock 499 $18.51 Direct F5
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -5.13K -5.73% $0.00 84.4K 06 Jun 2023 Common Stock 5.13K $18.51 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
F5 This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.